Rosiglitazone REMS arrives in November

Traynor, Kate
July 2011
American Journal of Health-System Pharmacy;7/1/2011, Vol. 68 Issue 13, p1176
Academic Journal
The article offers details related to the risk evaluation and mitigation strategy (REMS) for rosiglitazone-containing products, set to commence in November 2011, to reduce the risk of adverse ischemic cardiovascular events in type 2 diabetes mellitus patients. Information on GlaxoSmithKline's three products affected by the REMS is offered along with an overview of the new rosiglitazone distribution program and its implications on pharmacies and patients.


Related Articles

  • Rosiglitazone-containing antidiabetes medicines: suspension of marketing authorization.  // WHO Drug Information;2010, Vol. 24 Issue 4, p305 

    The article reports on a 2010 decision which the European Medicines Agency made to recommended suspension of the marketing authorizations for the rosiglitazone-containing antidiabetes drugs Avandia, Avandamet and Avaglim.

  • FDA issues alert for sale of illegal diabetes treatments.  // Endocrine Today;Aug2013, Vol. 12 Issue 8, p38 

    The article reports on the announcement by the U.S. Food and Drug Administration (FDA) that it will take regulatory action against 15 companies that currently sell illegally marketed diabetes products.

  • FDA evaluates diabetes drugs for possible increased risk of pancreatitis, precancerous cellular changes of pancreas. Walker, Tracey // Formulary;Apr2013, Vol. 48 Issue 4, p148 

    The article presents information on several diabetes drugs that are being evaluated by the U.S. Food & Drug Administration (FDA) for the potential risk of pancreatitis and precancerous changes of the pancreas. The drugs include exenatide, saxagliptin, and linagliptin. It is stated that these...

  • Challenges for FDA Mount.  // Chain Drug Review;4/26/2010, Vol. 32 Issue 8, p223 

    The article reports on the challenges faced by the Food and Drug Administration in protecting Americans from contaminated drugs in the U.S.

  • Pioglitazone: potential bladder cancer.  // WHO Drug Information;2010, Vol. 24 Issue 4, p301 

    The article reports on a 2010 decision which the U.S. Food and Drug Administration made to review data from an ongoing, ten year epidemiological study designed to evaluate whether the drug pioglitazone is associated with an increased risk of bladder cancer.

  • Actos and bladder cancer risk. Elliott, William T. // Primary Care Reports;Aug2011 Pharmacology Watch, p2 

    The article reports that the U.S. Food and Drug Association (FDA) has issued a warning regarding the use of the diabetes drug pioglitazone and risk of bladder cancer.

  • Actos.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10 

    The article reports on the safety review of the diabetic drug, Actos (pioglitazone), conducted by the U.S. Food and Drug Administration (FDA) to determine the association between Actos and the risk of bladder cancer.

  • Concerns about Rezulin grow even stronger. Cerrato, Paul L. // RN;Jul99, Vol. 62 Issue 7, p92 

    Reports on the precautions issued by the United States Food and Drug Administration on the use of antidiabetic agent troglitazone.

  • FDA approved saxagliptin to treat type 2 diabetes.  // Hem/Onc Today;9/10/2009, Vol. 10 Issue 17, p34 

    The article announces that the U.S. Food and Drug Administration (FDA) has approved saxagliptin, an oral hypoglycemic drug, as a treatment for type 2 diabetes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics